Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

Some school districts, including MSCS, have what's called a self-funded health plan. That means the employer pays for ...

The District 60 Board of Education unanimously approved a resolution hiring the Frantz Law Group Tuesday at the Lincoln Center administration building in Waukegan to help it recoup some of the ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The decision makes it impossible to guess what might come next for the healthcare industry. Robert F. Kennedy Jr. is unlike ...

London-listed GSK Plc and France’s Sanofi SA saw similar declines, with Deutsche Bank analyst Emmanuel Papadakis cutting his ...

If confirmed as the HHS Secretary by the US Senate, RFK Jr will oversee federal agencies that dictate healthcare policy in ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.